Piper Sandler raised the firm’s price target on Corebridge (CRBG) to $40 from $38 and keeps an Overweight rating on the shares. The firm is reducing its EPS estimates in the space driven by continued fee and spread headwinds. This was confirmed by a rather challenging pre-announcement of variable investment income from MetLife (MET) in late June suggesting this swing factor for a large chunk of lifecoland got sequentially worse, which also – in Piper’s opinion – pushes out the normalization factor towards 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBG:
- Corebridge price target raised to $42 from $37 at Wells Fargo
- Corebridge Financial’s Strategic Transaction Boosts Valuation and Shareholder Returns
- Corebridge price target raised to $44 from $43 at BMO Capital
- Corebridge Financial’s Strategic Moves and Reinsurance Agreement Justify Buy Rating
- Corebridge price target raised to $40 from $37 at Morgan Stanley